Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference
September 04 2020 - 7:00AM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that Ian Taylor, Ph.D., Chief
Scientific Officer, will participate in a fireside chat at the Citi
15th Annual BioPharma Virtual Conference on Thursday,
September 10 at 2:25 p.m. ET.
A live audio webcast of the presentation will be available here
and on Arvinas’ website at www.arvinas.com. A replay of the webcast
will be archived on Arvinas’ website for 30 days following the
presentation.
About Arvinas Arvinas is a clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients suffering from debilitating and life-threatening diseases
through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its
proprietary technology platform to engineer proteolysis targeting
chimeras, or PROTAC® targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. The company has two clinical-stage programs: ARV-110 for
the treatment of men with metastatic castrate-resistant prostate
cancer; and ARV-471 for the treatment of patients with locally
advanced or metastatic ER+/HER2- breast cancer. For more
information, visit www.arvinas.com.
Contacts for Arvinas
InvestorsWill O’Connor, Stern Investor Relations
ir@arvinas.com
MediaKirsten Owens, Arvinas
Communicationskirsten.owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2023 to Apr 2024